CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.21 USD
+0.02 (1.68%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.20 -0.01 (-0.83%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for CytomX Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -0.57 | -99.32 | -83.61 | -32.89 | -102.24 |
Depreciation/Amortization & Depletion | -5.24 | 2.39 | 2.98 | 2.34 | 0.38 |
Net Change from Assets/Liabilities | -62.51 | -30.65 | -54.70 | 18.13 | -59.32 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 12.29 | 16.79 | 16.30 | 17.67 | 20.70 |
Net Cash From Operating Activities | -56.04 | -110.79 | -119.03 | 5.26 | -140.48 |
Property & Equipment | -0.84 | -1.74 | -1.61 | -2.31 | -3.50 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -149.83 | 100.00 | 24.10 | -16.41 | 83.20 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -150.67 | 98.26 | 22.49 | -18.72 | 79.70 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 30.23 | 0.65 | 110.21 | 16.89 | 1.63 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 30.23 | 0.65 | 110.21 | 16.89 | 1.63 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -176.48 | -11.88 | 13.67 | 3.43 | -59.15 |
Cash at Beginning of Period | 194.57 | 206.45 | 192.78 | 189.34 | 248.49 |
Cash at End of Period | 18.09 | 194.57 | 206.45 | 192.78 | 189.34 |
Diluted Net EPS | -0.01 | -1.51 | -1.30 | -0.71 | -2.26 |
Fiscal Year End for CytomX Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 7.26 | 13.79 | -0.57 | -1.41 | -4.40 |
Depreciation/Amortization & Depletion | -2.38 | -1.40 | -5.24 | -3.50 | -2.06 |
Net Change from Assets/Liabilities | -56.26 | -41.33 | -62.51 | -37.93 | -15.98 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.78 | 2.89 | 12.29 | 8.77 | 6.60 |
Net Cash From Operating Activities | -45.59 | -26.05 | -56.04 | -34.07 | -15.83 |
Property & Equipment | -0.21 | -0.12 | -0.84 | -0.57 | -0.57 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 66.61 | 45.00 | -149.83 | -162.97 | -120.04 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 66.40 | 44.89 | -150.67 | -163.54 | -120.60 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 5.27 | 0.17 | 30.23 | 29.99 | 0.32 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 5.27 | 0.17 | 30.23 | 29.99 | 0.32 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 26.08 | 19.01 | -176.48 | -167.63 | -136.11 |
Cash at Beginning of Period | 18.09 | 18.09 | 194.57 | 194.57 | 194.57 |
Cash at End of Period | 44.16 | 37.10 | 18.09 | 26.94 | 58.45 |
Diluted Net EPS | -0.08 | 0.17 | 0.02 | 0.04 | -0.02 |